Showing 61-70 of 2038 results for "".
Norlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchZeiss MEL 90 Approved by FDA
https://modernod.com/podcasts/eyewire-news-the-podcast/zeiss-mel-90-approved-by-fda/37068/Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoicesGlaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit mB+L Bolsters Glaucoma Offerings with Elios Acquisition
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-bolsters-glaucoma-offerings-with-elios-acquisition/37063/Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhakic IOL for Presbyopia Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/phakic-iol-for-presbyopia-approved-in-europe/37061/A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoicesPotential Treatment Found for Age and Diabetes-Induced Eye Disease
https://modernod.com/articles/significant-findings/potential-treatment-found-for-age-and-diabetes-induced-eye-disease/37735/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatTapping the Glaucoma Market
https://modernod.com/topics/glaucoma/tapping-the-glaucoma-market/37961/There are good reasons for optometrists to seize this opportunity.Optic Nerve Hemorrhages and Glaucoma
https://modernod.com/topics/glaucoma/optic-nerve-hemorrhages-and-glaucoma/38517/Sometimes learning from our predecessors can be just as important as keeping up with the latest trends.Fish Oil Pills, the Shingles Vaccine, Oh Eye!
https://modernod.com/articles/significant-findings/fish-oil-pills-the-shingles-vaccine-oh-eye/37837/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curat